ESR1 and breast carcinoma: AMEERA-3 was a prospective, open-label, randomized phase 2 study to assess the safety and efficacy of amcenestrant compared to the ET of the physician’s choice in patients with ER+/HER2− metastatic or locally advanced breast cancer or metastatic breast cancer that progressed on ET.